Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Phillips

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
The Prostate|March 10, 2018
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortalityJonathan Hayman, Ryan Phillips, Di Chen, et al.
Advances in Radiation Oncology|April 14, 2020
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate CancerWilliam T Hrinivich, Ryan Phillips, Angela J Da Silva, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 9, 2022
Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysisAisling S Barry, Joelle Helou, Andrea Bezjak, et al.
The Journal of Urology|November 9, 2022
Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate CancerJack R Andrews, Mohamed E Ahmed, Vidit Sharma, et al.
Epidemiology and Infection|November 30, 2023
An outbreak of <i>Salmonella Typhimurium</i> associated with the consumption of raw liver at an Eid al-Adha celebration in Wales (UK), July 2021James P Adamson, Clare Sawyer, Gemma Hobson, et al.
Annals of Translational Medicine|July 21, 2025
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapyMiguel Muniz, Daniel S Childs, Jack Andrews, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2019
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins ExperienceMatthew P Deek, Colburn Yu, Ryan Phillips, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2024
Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomicsYufeng Cao, Philip Sutera, William Silva Mendes, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate CancerNeil R Parikh, Eric M Chang, Nicholas G Nickols, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
The Prostate|March 10, 2018
Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortalityJonathan Hayman, Ryan Phillips, Di Chen, et al.
Advances in Radiation Oncology|April 14, 2020
Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate CancerWilliam T Hrinivich, Ryan Phillips, Angela J Da Silva, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 9, 2022
Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysisAisling S Barry, Joelle Helou, Andrea Bezjak, et al.
The Journal of Urology|November 9, 2022
Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate CancerJack R Andrews, Mohamed E Ahmed, Vidit Sharma, et al.
Epidemiology and Infection|November 30, 2023
An outbreak of <i>Salmonella Typhimurium</i> associated with the consumption of raw liver at an Eid al-Adha celebration in Wales (UK), July 2021James P Adamson, Clare Sawyer, Gemma Hobson, et al.
Annals of Translational Medicine|July 21, 2025
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapyMiguel Muniz, Daniel S Childs, Jack Andrews, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2019
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins ExperienceMatthew P Deek, Colburn Yu, Ryan Phillips, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2024
Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomicsYufeng Cao, Philip Sutera, William Silva Mendes, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate CancerNeil R Parikh, Eric M Chang, Nicholas G Nickols, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial CohortsJack R Andrews, Yohan Kim, Edlira Horjeti, et al.
Pageof 10